Cotinga Pharmaceuticals Inc COTQF

Healthcare Biotechnology

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

GREY:COTQF - Post by User

Cotinga Pharmaceuticals Inc

Bullboard Posts

Comment by Actuarialon Dec 21, 2016 12:24pm

335 Views

Post# 25630299

RE:RE:RE:RE:RE:Share price falling, falling, falling

Agreed. Based on statistics, 5 out of 5000 candidates in preclinical got a chance enter into clinical; 1 out of 5 candidates in clinical finally got FDA approval. On average, it costs 14 years and $1.5B to develop a drug. Now we have a good odds. Expected value of COTI-2 is around $300M = $1.5B*20%= $1.5 per share = $300M / 200M share (projected) in 4 years. At the current price, it is a pretty good investment.

Bullboard Posts

Changing Europe’s dependency on HREE from China